Panobinostat in combination with bortezomib and dexamethasone demonstrated a significant and clinically meaningful progression-free survival benefit compared with placebo, bortezomib and dexamethasone in the phase 3 PANORAMA 1 (Panobinostat Oral in Multiple Myeloma 1) trial. Despite this benefit, patients in the panobinostat arm experienced higher rates of adverse events (AEs) and higher rates of discontinuation due to AEs. This PANORAMA 1 subanalysis examined AEs between 2 treatment phases of the study (TP1 and TP2), in which administration frequency of bortezomib and dexamethasone differed per protocol. The incidences of several key AEs were lower in both arms following the planned reduction of bortezomib dosing frequency in TP2. In the panobinostat arm, rates of thrombocytopenia (grade 3/4: TP1, 56Á7%; TP2, 6Á0%), diarrhoea (grade 3/4: TP1, 24Á1%; TP2, 7Á1%), and fatigue (grade 3/4: TP1, 16Á3%; TP2, 1Á8%) were lower in TP2 compared with TP1. Dose intensity analysis of panobinostat and bortezomib by cycle in the panobinostat arm showed reductions of both agent doses during cycles 1-4 due to dose adjustments for AEs. Exposure-adjusted analysis demonstrated a reduction in thrombocytopenia frequency in TP1 following dose adjustment. These results suggest that optimization of dosing with this regimen could improve tolerability, potentially leading to improved patient outcomes.
Over the past decade, tremendous progress has been made in the treatment of multiple myeloma (Kumar et al, 2008) . However, due to the clonal nature of the disease, relapse remains a near inevitability, and with each successive relapse, the duration of response to subsequent therapy decreases (Kumar et al, 2004) . Further complicating the therapeutic landscape, the majority of patients will eventually become refractory to available therapies, leading to poor prognosis and diminishing treatment options (Kumar et al, 2012) . Thus, there remains a clear unmet need for novel therapeutic options, particularly for patients with relapsed or relapsed and refractory multiple myeloma.
Panobinostat (PAN), a potent pan-deacetylase inhibitor, was recently approved by the US Food and Drug Administration and European Medicines Agency for the treatment of patients with relapsed or relapsed and refractory multiple myeloma who have received ≥2 prior treatment regimens, including bortezomib (BTZ) and an immunomodulatory drug. PAN is the first drug with a novel mechanism of action to be approved for patients with multiple myeloma in more than a decade. PAN exerts antimyeloma activity through both the epigenetic regulation of genes that are silenced in multiple myeloma and the inhibition of aggressome formation and blockade of protein metabolism (Atadja, 2009) . Furthermore, PAN has demonstrated significant preclinical synergy with the proteasome inhibitor BTZ that is thought to be linked to both epigenetic processes and inhibition of protein metabolism (Catley et al, 2006; Kikuchi et al, 2010; Ocio et al, 2010; Hideshima et al, 2011) .
The randomized, double-blind, phase 3 PANORAMA 1 (Panobinostat Oral in Multiple Myeloma 1) trial compared PAN in combination with BTZ and dexamethasone (Dex) versus placebo (Pbo) plus BTZ and Dex in patients with relapsed or relapsed and refractory multiple myeloma (SanMiguel et al, 2014) . PANORAMA 1 consisted of 2 distinct treatment phases (TP1 and TP2). In TP1, patients received PAN plus BTZ (twice weekly intravenously [IV] ) and Dex on the days of and after bortezomib over eight 3-week cycles. Patients achieving at least stable disease during TP1 could proceed to TP2, when PAN dosing was maintained as in TP1 and BTZ administration was reduced to once weekly, with Dex given on the days of and after bortezomib. The median duration of treatment was 4Á99 months in the PAN arm and 6Á14 months in the Pbo arm. Analysis showed significantly and clinically meaningful longer progression-free survival (PFS) in patients in the PAN arm compared with those in the Pbo arm (median: PAN-BTZDex, 12Á0 months [95% confidence interval (CI), 10Á33-12Á94] versus Pbo-BTZ-Dex, 8Á1 months [95% CI, 7Á56-9Á23]; hazard ratio: 0Á63 [95% CI, 0Á52-0Á76]; P < 0Á00001), despite a shorter duration of treatment. The difference in median PFS was much greater (7Á8 months) in patients who had received ≥2 prior treatment regimens, including BTZ and an immunomodulatory drug (Richardson et al, 2016) . Overall, a high number of adverse events (AEs) was reported in both treatment arms (all grade, 99Á7% in each arm), and patients in the PAN arm experienced higher rates of grade 3/4 AEs (95Á5% vs. 82Á2%), including thrombocytopenia (57Á0% vs. 24Á9%), diarrhoea (25Á5% vs. 8Á0%), and fatigue (17Á1% vs. 48Á8%). The mitigation of PAN-BTZ-Dex AEs and extension of treatment duration may be critical given that longer treatment duration may be associated with further improvement of disease control and patient outcomes.
The present subanalysis sought to elucidate the impact of treatment duration, dosing of PAN and BTZ, and administration frequency of BTZ and Dex on the safety and tolerability of the PAN-BTZ-Dex regimen in patients in the PANORAMA 1 trial. Dose intensity and AEs by cycle were analysed, and AE frequency between TP1 and TP2, when BTZ and Dex administration frequencies were reduced, was compared.
Methods

Study design and patients
The randomized, multicentre, placebo-controlled, doubleblind, phase 3 PANORAMA 1 trial assessed the efficacy and safety of PAN-BTZ-Dex versus Pbo-BTZ-Dex in patients with relapsed or relapsed and refractory multiple myeloma. Full inclusion criteria for the PANORAMA 1 trial have been previously reported (San-Miguel et al, 2014) . Briefly, eligible patients presented with relapsed or relapsed and refractory multiple myeloma treated with 1-3 prior treatments and an Eastern Cooperative Oncology Group performance status ≤2. 
Outcomes
The primary endpoint for the PANORAMA 1 trial was PFS (per investigator assessment based on modified European Blood and Marrow Transplantation criteria [San-Miguel et al, 2014] ). PFS was defined as the time from randomization until documented disease progression, relapse from complete response (CR) or death, whichever came first. Secondary endpoints included overall survival, overall response rate, near CR/CR rate, and safety (San-Miguel et al, 2014) . AEs were assessed according to the Common Toxicity Criteria for Adverse Events version 3.0 (http://ctep.cancer.gov/pro tocolDevelopment/electronic_applications/docs/ctcaev3.pdf).
Statistical analyses
Adverse events were analysed by treatment cycle and for patients completing TP1 and those completing TP2. Assessment of AEs following BTZ and Dex administration change in TP2 was complicated by the corresponding increase in cycle length from 3 to 6 weeks. To compensate for the difference in cycle length, an exposure-adjusted incidence-rate analysis was performed, normalizing the rate of AEs by mean duration of exposure over a 21-day period using the following formula: ([Number of patients with AE during cycle] 9 [100] 9 [21 days]) Ä ([Number of patients at risk] 9 [mean exposure for that cycle]) (Rothman, 2012) . The rate represents patients with AEs when 100 patients were exposed for 21 days. The group of patients completing TP2 was a subset of those who completed TP1; therefore, comparisons between these 2 groups should be interpreted with caution.
Results
Patients
A total of 768 patients were enrolled in PANORAMA 1 and randomly assigned to receive either PAN-BTZ-Dex (n = 387) or Pbo-BTZ-Dex (n = 381) as previously described (San-Miguel et al, 2014) . Of those, 169 patients in the PAN-BTZ-Dex arm and 192 patients in the Pbo-BTZ-Dex arm completed TP1 (and received ≥1 dose of study drug in TP2); among those, 102 patients in both the PAN and Pbo arms completed all 12 cycles of study treatment per protocol. Patients who completed TP1 and TP2 had similar baseline characteristics as the overall study population (Table I) . Compared with the overall population, patients who completed TP1 or TP2 had moderately less advanced disease by International Staging System classification (stage 1: 40Á1% vs. 48Á2% vs. 51Á5% for the overall population and those who completed TP1 and TP2, respectively) and were more likely to present with relapsed disease (62Á8% vs. 67Á3% vs. 72Á1%). Additionally, patients completing TP2 were less likely to have received prior BTZ compared with the overall population (43Á0% vs. 35Á3%). The proportion of patients completing all 12 cycles of therapy was nearly identical between treatment arms (PAN-BTZ-Dex, 26Á4% vs. Pbo-BTZ-Dex, 26Á8%). However, nearly twice as many patients in the PAN-BTZ-Dex arm discontinued therapy due to AEs compared with patients in the Pbo-BTZ-Dex arm (33Á6% vs. 17Á3%), with the majority of discontinuations occurring in TP1 across both arms (PAN-BTZ-Dex, 28Á9%; Pbo-BTZDex, 16Á5%). Conversely, patients in the Pbo-BTZ-Dex arm discontinued therapy due to progressive disease at nearly twice the rate of patients in the PAN-BTZ-Dex arm (40Á2% vs. 21Á2%) (Table II) .
Safety
The median dose intensity of PAN was 4Á7 mg/day in TP1 vs. 4Á3 mg/day in TP2. Due to the protocol-planned reduction in the frequency of administration of BTZ and Dex in TP2, the median dose intensities of both drugs were correspondingly lower in TP2 ( Figure S1 ) (BTZ in both arms, 0Á2 mg/day in TP1 vs. 0Á1 mg/day in TP2; PAN-BTZ-Dex, Dex 6Á7 mg/day in TP1 vs. 3Á7 mg/day in TP2; Pbo-BTZDex, Dex 7Á2 mg/day in TP1 vs. 3Á8 mg/day in TP2).
Overall, the rate of several key AEs decreased in both treatment arms during TP2 with the reduced frequency of BTZ and Dex administration (Table III) . Notably, the rates of grade 3/4 AEs of diarrhoea (PAN-BTZ-Dex, 24Á1% TP1 vs. 7Á1% TP2; Pbo-BTZ-Dex, 8Á0% TP1 vs. 0% TP2), thrombocytopenia (PAN-BTZ-Dex, 56Á7% TP1 vs. 6Á0% TP2; Pbo-BTZ-Dex, 24Á4% TP1 vs. 1Á0% TP2), anaemia (PAN-BTZ-Dex, 15Á5% TP1 vs. 3Á0% TP2; Pbo-BTZ-Dex, 15Á1% TP1 vs. 3Á6% TP2), and fatigue (PAN-BTZ-Dex, 16Á3% TP1 vs. 1Á8% TP2; Pbo-BTZ-Dex, 8Á8% TP1 vs. 0% Table II . Patient disposition.
Primary reason for end of treatment, n (%)
Overall
During TP1 (cycles 1-8) 
BTZ, bortezomib; Dex, dexamethasone; PAN, panobinostat; Pbo, placebo; TP, treatment phase. *One patient randomly assigned to receive PAN was given Pbo during cycles 1 and 2 because of a misallocation error; the patient was subsequently given PAN from cycle 3 until discontinuation of treatment but was included in the Pbo group for the safety analysis. TP2) were substantially reduced across both arms during TP2 (Table III) . Similarly, the incidence of new or worsening grade 3/4 AEs among patients who completed TP2 decreased in both arms during TP2 compared with TP1. Of note, in the PAN arm, this included marked decreases in the rates of grade 3/4 AEs of interest, including thrombocytopenia (TP1, 47Á1% vs. TP2, 5Á9%), diarrhoea (25Á5% vs. 8Á8%) and fatigue (14Á7% vs. 2Á0%) (Table IV) . When analysed by treatment cycle, the rate of thrombocytopenia among patients completing TP2 in the PAN arm decreased from cycle 2 through cycle 6 of TP1 (per-cycle allgrade rate: cycle 2, 47Á1%; cycle 3, 45Á1%; cycle 4, 35Á3%; cycle 5, 30Á4%; cycle 6, 23Á5%) (Fig 1) . Notably, this decrease followed a decrease in the median dose intensity of both PAN and BTZ due to initial dose reductions ( Figure S1 ). A further decrease in both the all-grade and grade 3/4 rates of thrombocytopenia was observed during TP2 when administration doses of BTZ and Dex were reduced and PAN exposure remained constant, with the incidence of all-grade AEs decreasing by half from cycles 8-9 (28Á4% vs. 14Á7%) and the incidence of grade ≥3 AEs decreasing 4-fold (11Á8% vs. 2Á9%) (Fig 1; Figure S1 ). These results were consistent when 
BTZ, bortezomib; Dex, dexamethasone; PAN, panobinostat; Pbo, placebo; TP, treatment phase. *Newly occurring or worsening adverse events. The rate represents patients with adverse events when 100 patients were exposed to panobinostat for 21 days.
All grades
analysed as an overall per-cycle rate or when adjusted for the differential exposure in TP2 due to increased cycle length. Diarrhoea, another notable AE in patients treated with PAN-BTZ-Dex, showed no substantial decrease in the overall per-cycle rate during either the initial dose reduction or following BTZ and Dex dose reductions in TP2 among patients in the PAN-BTZ-Dex arm who completed TP2. However, when the rate was normalized by drug exposure to account for increased cycle length in TP2, a decrease in the all-grade exposure-adjusted rate of diarrhoea was observed during TP2 (cycle 8 vs. cycle 9, 31Á3% vs. 16Á3%) (Fig 2) . Similarly, there was no apparent decrease in the overall per-cycle rate of fatigue in patients completing TP2 in the PAN-BTZ-Dex arm associated with TP1 dose adjustment or the planned BTZ and Dex dose reductions in TP2. However, when the all-grade rate of fatigue was adjusted for the increased cycle length in TP2, a decrease in the rate was observed following the reduction of BTZ and Dex doses in TP2 (cycle 8 vs. cycle 9, 32Á2% vs. 17Á8%) (Fig 3) . The overall and exposureadjusted rates of these AEs for patients in the placebo arm who competed TP2 are shown in Figures S2-S4 .
Discussion
The overlapping safety profiles of single-agent PAN and BTZ, particularly with regard to potentially additive gastrointestinal side effects and thrombocytopenia, make proper dosing of these agents critical when used in combination to reduce toxicity and enhance patient outcomes. The analyses presented here suggest that dose adjustment or optimization of the PAN, BTZ, and/or Dex regimen could substantially reduce the rate of key AEs observed in patients treated with the PAN-BTZ-Dex combination, potentially leading to fewer AE-associated dose interruptions or discontinuations. In the PANORAMA 1 trial, the addition of PAN to BTZ and Dex has demonstrated clinically meaningful and significant The rate represents patients with adverse events when 100 patients were exposed to panobinostat for 21 days. The rate represents patients with adverse events when 100 patients were exposed to panobinostat for 21 days.
All grades
Impact of Dose Intensity on Safety in PANORAMA 1 ª 2017 John Wiley & Sons Ltd efficacy benefit, with an increase in median PFS of % 4 months (PAN-BTZ-Dex, 12Á0 months vs. Pbo-BTZ-Dex, 8Á1 months; P < 0Á0001) (San-Miguel et al, 2014) in the overall population. However, compared with patients in the Pbo-BTZ-Dex arm in PANORAMA 1, patients in the PAN-BTZ-Dex arm discontinued treatment due to AEs at nearly twice the rate (33Á6% vs. 17Á3%), whereas the rate of discontinuation due to disease progression was almost half (21Á2% vs. 40Á2%).
One of the main safety observations in this study was the reduction in the frequency of key grade 3/4 AEs, including thrombocytopenia (grade 3/4 PAN-BTZ-Dex arm: TP1, 47Á1%; TP2, 5Á9%), diarrhoea (grade 3/4 PAN-BTZ-Dex arm: TP1, 25Á5%; TP2, 8Á8%) and fatigue (grade 3/4 PAN-BTZ-Dex arm: TP1, 14Á7%; TP2, 2Á0%), during TP2 compared with TP1, following a planned reduction in the administration frequency of BTZ and Dex. A reduction in AE rates in later cycles could potentially be confounded by selecting patients who were better able to tolerate the regimen or fared better on treatment because only those who were deriving at least a clinical benefit could advance from TP1 to TP2 and only those who completed TP2 were included in that group. However, the striking decrease in exposure-adjusted rates of thrombocytopenia, diarrhoea and fatigue from cycle 8-9 among patients in the PAN-BTZ-Dex arm who completed TP1 suggests that the reduced frequency of BTZ and/or Dex administration had a substantial impact on toxicity. Once-weekly administration of BTZ has been previously associated with a significant reduction in the incidence of non-haematological AEs and grade 3/4 peripheral neuropathy while demonstrating equivalent efficacy (Mateos et al, 2010) . Together, these results suggest that combining PAN with once-weekly BTZ plus Dex on the days of and following BTZ administration could provide one potential strategy for optimization of the regimen.
We also observed a decrease in the per-cycle rate of thrombocytopenia during the early cycles of TP1 that followed the decrease in the median dose intensity of both PAN and BTZ due to dose adjustments in the first 4 cycles. Both PAN and BTZ have been shown to induce thrombocytopenia through a reversible blockade of megakaryocyte maturation and the reduced release of proplatelets, suggesting an overlapping effect that is probably mitigated through dose adjustment (Lonial et al, 2005; Bishton et al, 2011; Giver et al, 2011) . Although an association between decreasing PAN and BTZ dose intensities during initial dose reduction and the rate of diarrhoea is difficult to determine in this study, patients treated with a combination of PAN and a lower dose of BTZ (1Á0 mg/m 2 ) in a previous study experienced a lower overall incidence of diarrhoea and no grade 3/4 diarrhoea in a small cohort (San-Miguel et al, 2014) . Therefore, reduction in the starting dose of BTZ could help to improve the risk/benefit profile of the PAN-BTZ-Dex regimen and warrants further investigation to determine optimal dosing.
A limitation of the PANORAMA 1 trial was its initiation when the IV administration of BTZ was the standard of care. Subsequent studies have shown not only similar pharmacokinetics and 20S proteasome inhibition (Moreau et al, 2008) between subcutaneous and IV BTZ but have also demonstrated non-inferior efficacy and an improved safety profile with subcutaneous versus IV BTZ, characterized by a reduction in the rate of peripheral neuropathy (Moreau et al, 2011) . Moreover, patients receiving subcutaneous BTZ experienced substantially fewer gastrointestinal AEs compared with IV administration (37% vs. 58%). Incorporation of subcutaneous BTZ in the PAN-BTZ-Dex regimen in the future could help reduce the toxicity of the regimen and prevent dose delay/interruption or discontinuation. Additionally, subcutaneous BTZ administration may provide quality of life benefits (Barbee et al, 2013) .
Analyses of other trials in relapsed and refractory multiple myeloma have shown that prolonged treatment is associated with improved outcomes. A subanalysis of the MM-009 and MM-010 studies demonstrated that, among patients treated with a combination of lenalidomide and Dex who achieved at least a partial response, those who continued treatment had a significantly prolonged overall survival compared with patients who discontinued without progression (San-Miguel et al, 2011) . However, the benefits of remaining on treatment to achieve better PFS must be balanced with the quality of life of the patient and minimizing toxicity. Taken together, these results highlight the importance of prolonging the duration of therapy and underscore the need to optimize the PAN-BTZ-Dex regimen and mitigate key AEs.
Ultimately, the management of AEs with the PAN-BTZ-Dex regimen through optimization of dosing and administration, as well as improvements in the clinical management of common AEs, will be important for prolonging the duration of PAN-BTZ-Dex therapy, potentially improving patient outcomes.
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